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Abstract
Background: Oestrogen-deficiency induced by menopause is associated with reduced bone density and primary
osteoporosis, resulting in an increased risk of fracture. While the exact etiology of menopause-induced primary
osteoporotic bone loss is not fully known, members of the tumour necrosis factor super family (TNFSF) are known
to play a role. Recent studies have revealed that the TNFSF members death receptor 3 (DR3) and one of its ligands,
TNF-like protein 1A (TL1A) have a key role in secondary osteoporosis; enhancing CD14+ peripheral blood
mononuclear cell (PBMC) osteoclast formation and bone resorption. Whether DR3 and TL1A contribute towards
bone loss in menopause-induced primary osteoporosis however, remains unknown.
Methods: To investigate this we performed flow cytometry analysis of DR3 expression on CD14+ PBMCs isolated
from pre- and early post-menopausal females and late post-menopausal osteoporotic patients. Serum levels of
TL1A, CCL3 and total MMP-9 were measured by ELISA. In vitro osteoclast differentiation assays were performed to
determine CD14+ monocyte osteoclastogenic potential. In addition, splenic CD4+ T cell DR3 expression was
investigated 1 week and 8 weeks post-surgery, using the murine ovariectomy model.
Results: In contrast to pre-menopausal females, CD14+ monocytes isolated from post-menopausal females were
unable to induce DR3 expression. Serum TL1A levels were decreased approx. 2-fold in early post-menopausal
females compared to pre-menopausal controls and post-menopausal osteoporotic females; no difference was
observed between pre-menopausal and late post-menopausal osteoporotic females. Analysis of in vitro CD14+
monocyte osteoclastogenic potential revealed no significant difference between the post-menopausal and post-
menopausal osteoporotic cohorts. Interestingly, in the murine ovariectomy model splenic CD4+ T cell DR3
expression was significantly increased at 1 week but not 8 weeks post-surgery when compared to the sham control.
Conclusion: Our results reveals for the first time that loss of oestrogen has a significant effect on DR3; decreasing
expression on CD14+ monocytes and increasing expression on CD4+ T cells. These data suggest that while
oestrogen-deficiency induced changes in DR3 expression do not affect late post-menopausal bone loss they could
potentially have an indirect role in early menopausal bone loss through the modulation of T cell activity.
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Background
Osteoporosis is characterized by micro-architectural deteri-
oration of bone tissue and low bone mass that conse-
quently results in increased bone fragility and susceptibility
to fracture [1]. In the United Kingdom more than 3 million
people are estimated to have osteoporosis with 500,000
osteoporotic fractures every year; costing an estimated £1.8
billion in 2000 with a potential increase to £2.2 billion by
2025 [2, 3]. Osteoporosis can be characterized into two
main forms: primary osteoporosis which occurs as part of
aging and secondary osteoporosis, when bone loss is driven
by a medical condition / disease or treatment [4]. The onset
of menopause in females is a major factor in the develop-
ment of primary osteoporosis. Loss of oestrogen results in
two stages of bone loss: an early rapid loss of trabecular
and cortical bone due to increased osteoclast activity and
decreased osteoclast apoptosis, and a second slower pro-
longed loss due to decreased osteoblast activity [4, 5]. In
contrast, bone loss due to secondary osteoporosis is caused
by factors including but not limited to hyperparathyroid-
ism, inflammatory bowel disease (IBD), type 1 diabetes
(T1D), arthritis and glucocorticoid treatment. Several
mechanisms are known to contribute to the pathology of
menopause-induced primary osteoporosis such as increased
expression of tumour necrosis factor (TNF) superfamily
members TNFα (TNFSF2) and receptor activator of nu-
clear factor kappa-B ligand (RANKL; TNFSF11) [6–11]. It
is currently unknown however, what role other members of
the TNFSF play in this pathological bone loss. This study
focused on the TNFSF members TNF-like protein 1A
(TL1A, TNFSF15) and its only confirmed trans-membrane
receptor, death receptor 3 (DR3; TNFRSF25) [12].
DR3 and its ligand TL1A have been implicated in the
pathogenesis of numerous inflammatory conditions as-
sociated with secondary osteoporosis including: IBD and
rheumatoid arthritis (RA) [13–15]. While the majority of
DR3’s function has been attributed to its expression on
T cells and the ability of TL1A to drive the proliferation
of effector T cell subsets [16, 17], studies have identified
expression of DR3 on the surface of osteoclast precur-
sors and osteoblasts [14, 18, 19]. In vitro studies using
circulating CD14+ monocytes, osteoclast precursors
which migrate to bone to undergo differentiation into
osteoclasts [20], identified cell surface expression of DR3
and that addition of TL1A to these cells significantly en-
hanced osteoclast proliferation and resorptive activity;
increasing expression of the chemokine CCL3 and the
enzyme matrix metallopepetidase 9 (MMP9) [14]. Fur-
thermore, expression of DR3 has also been identified on
human osteoblasts (OB) where, in vitro, it mediated
apoptosis under narrowly regulated conditions [21].
These results suggest that signalling by TL1A through
DR3 on CD14+ osteoclast precursors and osteoblasts
could have an important direct role in the pathogenesis
of menopause-induced primary osteoporosis; increasing
bone resorption and decreasing bone formation. This is
further supported by in vivo studies in the murine
collagen-induced arthritis (CIA) model where ablation of
DR3 was shown to protect against secondary osteopor-
osis at sites distal from the small joints [14]. Further-
more, CD4+ T cells have been identified as being
significant drivers of bone loss following oestrogen defi-
ciency [22], leading to the possibility that changes in
DR3 / TL1A expression on these cells could potentially
have an indirect effect on bone loss.
While the current data suggests that DR3 and TL1A
are implicated in adverse bone loss associated with sec-
ondary osteoporosis, their complicity in the pathology of
menopause-induced primary osteoporosis remains
unknown. In the present study we investigated serum
levels of TL1A and the expression of DR3 on peripheral
blood CD14+ cells isolated from pre-menopausal, post-
menopausal and late post-menopausal osteoporotic fe-
males to determine whether changes in oestrogen status
result in significant modulation of these TNFSF mem-
bers. We demonstrate for the first time that, in contrast
to pre-menopausal females, post-menopausal serum
levels of TL1A are not significantly elevated and that
DR3 expression is not induced on CD14+ monocytes.
However, utilizing the murine ovariectomy (OVX) model
of oestrogen-deficiency we reveal that early post-OVX
expression of DR3 on CD4+ T cells is significantly ele-
vated suggesting that DR3 and TL1A could play a poten-
tially indirect role in early post-menopausal bone loss.
Methods
Ethical approval
Ethical approval for the isolation of patient blood was ob-
tained from the South East Wales Research Ethics Commit-
tee (REC reference number: 10/WSE02/44). Patients were
recruited to one of two cohorts: postmenopausal (n = 2)
and postmenopausal osteoporotic with fracture (n = 4). In-
clusion and exclusion criteria are outlined in Table 1. Pa-
tients with a t score lower than − 2.5 were deemed to be
osteoporotic. Pre-menopausal control (n = 6) and additional
post-menopausal control (n = 4) blood samples were
obtained in-house with ethical approval provided by the
Medical / Dental School Research Ethics Committee
(MDSREC Reference Number: 09/21).
Flow cytometry
Blood samples were collected in heparin coated tubes and
processed within 2 h. Peripheral blood mononuclear cells
(PBMCs) were isolated (pre-menopausal n = 6, post-
menopausal n = 6 and osteoporotic n = 4) by density gra-
dient centrifugation using Histopaque-1077 (Sigma), and
CD14+ monocytes isolated by magnetic cell sorting fol-
lowing manufacturer’s instructions (Miltenyi Biotec, UK).
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Cells were stained in phosphate buffered saline (PBS) con-
taining 1% (v/v) foetal calf serum (FCS) with anti-DR3-PE
(clone JD3) and anti-CD14-FITC (clone 61D3) (eBioscience)
for 30min at 4 °C. Data were acquired on an Accuri C6 flow
cytometer and analysed with FlowJo V10.
For murine splenic T cell analysis, spleens (n = 4–8)
were isolated and homogenized into a single cell suspen-
sion. Red blood cells were removed with 1x RBC lysis
buffer (eBioscience) according to manufacturer’s instruc-
tions. 1 × 106 cells were incubated with Fc block (BD
Pharmingen, CA, USA) for 15 min. Cells were stained
with anti-mouse CD4-eF450 (RM 4–5, eBioscience) and
anti-mouse DR3-PE (4C12, BioLegend) for 30 min at
4 °C. Data were acquired on a BD LSRII (Becton Dickin-
son, Franklin Lakes, NJ) and analysed with FlowJo (Ver-
sion 10; FlowJo, LLC, Ashland OR).
Osteoclastogenesis assays
Isolated CD14+ PBMCs (6.4 × 104) were added to ivory
discs in RPMI supplemented with 10% FCS, 20 mML-
glutamine and 50 μg/ml Penicillin/Streptomycin (RPMI-
10). After 2 h at 37 °C 5% CO2, discs were transferred to
48-well plates and RPMI-10 with macrophage colony
stimulating factor (MCSF; 5 ng/ml) added. Media was
replenished after 3 days and cells stained for DR3 after 7
days (classified as day 0 for OC assays). Media was
replenished every 3–4 days using RPMI-10 supple-
mented with MCSF (5 ng/ml), RANKL (5 ng/ml) and
anti-polyHistidine (2.5 μg/ml) all from R&D systems. Su-
pernatants were stored at − 80 °C for further analysis.
Two discs per condition were stained for tartrate resist-
ant acid phosphatase (TRAP) on day 14. Images of five
random areas of the discs were taken at × 10 magnifica-
tion using a BX41 microscope and Camedia C-3030
camera (Olympus, UK) and cropped to represent
1000 μm2 (Corel Paint Shop Pro, Corel, UK). The num-
ber of TRAP-positive multinucleated cells and TRAP-
negative/positive mononucleated cells were counted and
results reported per disc.
Patient serum analysis
Serum levels of TL1A (Peprotech, London, UK), the che-
mokine CCL3 and Total matrix metalloproteinase
(MMP)-9 (R&DSystems, Abingdon, UK) were measured
by ELISA according to manufacturer’s instructions.
Ovariectomy (OVX) surgeries
Female BALB/c mice, 11 weeks of age, were obtained
from The Jackson Laboratory (Bar Harbour, Maine).
Mice were allowed to acclimatize to the specific patho-
gen free animal facility for 1 week prior to start of ex-
periment. Animals were randomly split into two groups:
sham control or OVX (n = 4–8). For sham and OVX
surgeries, mice were anesthetized with isofluorane and a
2 cm lower mid-dorsal incision was made extending
through the skin and muscle layers. Ovaries were iso-
lated in both sham and OVX groups; ovaries were re-
moved from the OVX cohort and incision sites closed
using surgical staples in both sham and OVX mice. Mice
were assessed daily for welfare and surgical staples re-
moved 7 days post-surgery. Mice were housed in shoe-
box cages with environmental enrichment in groups of
4, provided with Teklad 2019 chow (Madison, WI) and
water ad libitum and maintained on a 12-h light/dark
cycle; all animal caretaking was performed by Michigan
State University campus animal resources personnel.
Mice were sacrificed in the morning 1 and 8 weeks post-
surgery by overdose of inhalation anaesthetic followed
by cervical dislocation. All animal procedures were ap-
proved by the Michigan State University Institutional
Animal Care and Use Committee and conformed to
NIH guidelines.
Statistical analysis
All measurements are presented as the mean ± SEM.
Unpaired t-test and 1-way ANOVA with Bonferroni or
Dunnett’s post-test were performed using GraphPad
Prism software version 6 (GraphPad, San Diego, CA,
USA). p-values of < 0.05 were considered significant and
p-values of < 0.01 highly significant.
Results
Patient bone parameters
Patient bone parameters were analysed by dual-energy X-
ray absorptiometry (DXA) at three sites: hip, spine and
neck of femur (Table 2). Bone mineral density (BMD) was
not significantly different between the patient cohorts at
the hip and spine. A significant decrease in neck of femur
BMD was observed in the osteoporosis cohort when com-
pared to the post-menopausal control (p < 0.01).
Table 1 Study Criteria
Inclusion Criteria Exclusion Criteria
Attending for first bone
density scan
Recent fracture (in the past 3 months)
Adult History of corticosteroid use
(except inhaled or topical)
Female Anti-TNF therapy
Post-Menopausal Patients with known seropositive rheumatoid
arthritis, inflammatory bowel disease
Recent history of continuous treatment
with bisphosphonate, calcitonin, Strontium
ranelate or parathyroid hormone
(i.e. for more than 3 months)
Patients with known primary
hyperparathyroidism
Currently taking part in another study
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Serum levels of TL1A, CCL3 and Total MMP-9
In autoimmune conditions such as rheumatoid arthritis
levels of serum TL1A are significantly increased [23].
Levels were measured in patient serum to determine
whether TL1A expression is a potential confounding fac-
tor in post-menopausal bone loss (Table 2). Interestingly,
a 1.9-fold decrease in levels of circulating TL1A was mea-
sured in post-menopausal controls compared to the pre-
menopausal controls, though this difference wasn’t signifi-
cant. However, serum levels of TL1A in osteoporotic pa-
tients were comparable to the pre-menopausal control.
Ex vivo osteoclast cultures of cells isolated from pre-
menopausal females revealed that TL1A induced expression
of the chemokine CCL3 and MMP-9 [14]. As with TL1A,
levels of serum CCL3 were decreased (2.4-fold) in the post-
menopausal controls compared to pre-menopausal controls.
Additionally, a 4.7-fold decrease was observed in the osteo-
porotic patients. In contrast to TL1A and CCL3 expression,
levels of total MMP-9 were comparable in the post-
menopausal controls but significantly increased in the osteo-
porotic patient serum (p < 0.05).
Expression of DR3 on circulating CD14+ PBMCs
To determine whether CD14+ osteoclast precursor DR3 ex-
pression is affected by menopause or osteoporosis, levels
were analysed on freshly isolated CD14+ cells by flow cy-
tometry (Fig. 1). No DR3 expression was detected on the
surface of CD14+ monocytes isolated from the post-
menopausal patients; comparable to that previously ob-
served with cells isolated from pre-menopausal females [14].
In contrast to pre-menopausal females however, no
upregulation of DR3 expression was observed on cells
isolated from post-menopausal females following culture
in the presence of MCSF on ivory discs for 7 days (Fig. 2).
To determine whether the cells required increased cul-
ture time for DR3 upregulation the culture period was
extended to 12 days in 3 of the post-menopausal control
samples. As with the 7 day time point no increase in
DR3 expression was observed.
CD14+ Osteoclastogenesis assays
Post-menopausal osteoporosis is characterized by a
period of increased osteoclast activity resulting in
Table 2 Characterisation of patients included in study
Pre-Menopausal Post-Menopausal Osteoporotic
Age (years) 21–32 54–58 68 ± 3
Hip BMD – 0.72 ± 0.08 0.68 ± 0.03
Spine BMD – 0.90 ± 0.06 0.83 ± 0.04
Neck of Femur BMD – 0.76 ± 0.03 0.55 ± 0.01b
Weight (kg) – 85.95 ± 11.65 62.73 ± 1.59
Serum TL1A (pg/ml) 123.5 ± 24.1 64.4 ± 22.9 117.3 ± 10.7
Serum CCL3 (pg/ml) 195.1 ± 88.3 82.6 ± 51.4 41.6 ± 30.4
Serum Total MMP-9 (ng/ml) 4.43 ± 0.2 5.12 ± 0.4 5.49 ± 0.1a
aSignificantly different to pre-menopausal; bSignificantly different to post-menopausal
a b
Fig. 1 Expression of DR3 on Freshly Isolated Post-menopausal Human CD14+ Monocyte Osteoclast Precursors. CD14+ monocytes were isolated
from post-menopausal females without (PM) (n = 6) and with osteoporosis (OP) (n = 4). DR3 expression was determined by flow cytometry. a
DR3 expression was not detected on freshly isolated CD14+ monocytes. b representative histograms of DR3 expression. (Shaded peak = isotype;
dark line = DR3 antibody)
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significant bone loss [24]. We investigated, ex vivo,
whether the lack of DR3 expression on post-menopausal
CD14+ monocytes affected osteoclastogenesis. At the ex-
periment endpoint (day 14), significantly elevated total
cell numbers were observed in the osteoporotic patient-
derived cultures compared to the post-menopausal con-
trols (p < 0.05; Fig. 3a). Somewhat surprisingly however,
no significant difference was observed between the cul-
tures for TRAP+ mononuclear cells and TRAP+ multi-
nucleated osteoclasts (Fig. 3b, c and d). Interestingly, the
number of osteoclasts generated by the CD14+ cells iso-
lated from the post-menopausal patients was approxi-
mately 3-fold lower than that previously reported from
pre-menopausal females using the same system [14].
This suggests that while DR3 expression is not essential,
its presence on precursors enhances osteoclastogenesis.
CD4+ T Cell DR3 expression following loss of Oestrogen
Previous studies have shown that osteoclast formation is
increased in PBMC cultures isolated from women 1 year
after menopause compared to women in menopause [7].
To determine whether DR3 expression could be playing
a role in early post-menopausal PBMC osteoclast forma-
tion we utilized the murine ovariectomy (OVX) model
of oestrogen-deficiency. Ovaries were removed from the
mice and DR3 expression on splenic CD4+ T cells deter-
mined 1 week and 8 weeks post-surgery by flow cytome-
try (Fig. 4). The number of CD4+ DR3+ cells (p < 0.05)
and DR3 expression (p < 0.01) was significantly in-
creased in the OVX cohort 1 week post-surgery com-
pared to the sham control. Eight weeks post-surgery
however, no difference in DR3 expression was observed
between the sham and OVX cohorts.
a
b
Fig. 2 Expression of DR3 on Cultured Post-menopausal Human CD14+ Monocyte Osteoclast Precursors. CD14+ monocytes were isolated from pre-
menopausal (Pre) (n = 6) and post-menopausal females, without (PM) (n = 6) and with osteoporosis (OP) (n = 4). Cells were cultured on ivory discs for 7
days in media + MCSF. DR3 expression was determined by flow cytometry. a Gating strategy for detection of DR3. b Fold difference in CD14+ monocyte
DR3 expression after 7 days and 12 days in culture. After 7 days pre-menopausal expression of DR3 was significantly elevated compared to the post-
menopausal (p < 0.01) and post-menopausal with osteoporosis (p < 0.05) cultures. DR3 expression was not induced on CD14+ cells isolated from post-
menopausal females after 12 days in culture. Statistical analysis performed by 1 way ANOVA with Dunnett’s multiple comparison test
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Discussion
The pathology of osteoporosis is complex with many
factors contributing to the increased bone loss and de-
creased bone formation. Of these factors, members of
the TNFSF such as TNFα and RANKL are known to
play critical roles. While roles for DR3 and its ligand
TL1A have been demonstrated in numerous conditions
that are associated with pathological bone loss [13–15],
it is currently unknown whether DR3 and / or TL1A are
affected by loss of oestrogen and contribute to the pro-
gression of menopause-induced primary osteoporosis. In
the present study we reveal for the first time in humans
that loss of oestrogen does not significantly affect serum
levels of TL1A and that late post-menopause CD14+
monocyte osteoclast precursors are unable to induce
DR3 expression. Furthermore, using the murine OVX
model of oestrogen-deficiency, we demonstrate that
early post-OVX DR3 expression is upregulated on CD4+
T cells but returns to normal levels at later time points,
when compared to the sham control (mice that have the
same surgery but whose ovaries remain intact). These
data suggest that DR3 and TL1A could have a potential
indirect role in increasing osteoclast formation and bone
loss in the early stages of post-menopause.
Oestrogen deficiency associated with menopause has
been linked to elevated levels of interleukin (IL)- 1β, IL-8
and TNFα in the serum [6] and increased expression of
RANKL and TNFα in ex vivo cultures of PBMCs [7, 8], cir-
culating monocytes [9] and bone marrow macrophages [10,
11]. In the present study, serum levels of TL1A were de-
creased in post-menopausal females but comparable in the
osteoporotic cohort when compared to the pre-menopausal
controls; suggesting that unlike TNFα, elevated expression
of TL1A does not play a role in post-menopausal osteopor-
otic bone loss. However, it is important to note that the in-
creased cytokine expression described in previous studies
[6–11] were reported in samples isolated from early post-
menopausal females. Interestingly, in the study by Bismar
et al. [10] cytokine levels in late post-menopausal (70 ± 6
years old) bone marrow cultures were significantly lower
than those from early post-menopausal women (51 ± 5
years old). These observations raise a couple of intriguing
possibilities: firstly, that TL1A may be increased during the
early stages of post-menopause when bone loss occurs but
missed during this study and secondly; that due to physio-
logical changes post-menopause, pre-menopausal levels of
TL1A become pathological and contribute to bone loss.
Having shown that serum levels of TL1A were not elevated
in late post-menopausal osteoporotic patients we next in-
vestigated the effect on DR3 to determine if increased re-
ceptor expression could contribute to the increased bone
loss associated with osteoporosis.
a
d
b c
Fig. 3 Osteoclastogenesis Assays CD14+ monocytes were isolated from post-menopausal females without (PM) (n = 6) and with osteoporosis (OP) (n = 4)
and cultured on ivory discs for 7 days in media + MCSF. Cells were differentiated for 14 days in the presence of MCSF and RANKL. At experiment end-
point cells were stained for TRAP. a Significantly increased cell number was observed in cultures derived from post-menopausal females with osteoporosis
(p < 0.05). No difference was observed in the number of (b) TRAP+ mononuclear cells or (c) multinucleated osteoclasts. d Representative images of
osteoclast cultures. Arrows indicate multinucleated TRAP+ osteoclasts. Statistical analysis performed by unpaired student’s t-test
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Previously we reported that circulating CD14+ mono-
cytes, isolated from pre-menopausal females, express
DR3 when cultured in the presence of MCSF on ivory
discs and that treatment of these cells with TL1A re-
sulted in significantly enhanced osteoclast formation
[14]. Interestingly however, in the present study DR3 ex-
pression was not induced on CD14+ monocytes isolated
from post-menopausal females, even when cultured for
an extended period. The difference in DR3 expression
between pre- and post-menopausal derived CD14+
monocytes suggests a critical change in these cells
caused by menopause. The effects of aging and meno-
pause on immune cell DR3 expression has not been ex-
tensively studied. In the only other study to investigate
the effect of aging on DR3 expression, Slebioda et al.
[25] noted differences in CD4+, CD8+ and CD20+ DR3
expression between healthy children (9.8 ± 4.3 years) and
healthy adults (45.3 ± 10.5 years); suggesting that aging
can have a significant effect on a cell’s DR3 phenotype.
While in the Slebioda et al. [25] study aging did not
affect CD14+ and CD11c+ DR3 expression, it does not
rule out a change in DR3 phenotype on these cells due
to menopause or as a person moves from adult (20–59
years) to elderly (60+ years); changes in monocyte and
macrophage functions have been documented as im-
paired in aged animal models [26] and elderly individ-
uals [27]. Furthermore, work by Sadeghi et al. [28]
demonstrated that monocytic CD14 expression alters
during aging; cells change from a CD14bright/CD16dim
phenotype in young individuals (30.5 ± 13.5 years) to a
CD14dim/CD16bright phenotype in the elderly (87.6 ± 14
years) demonstrating that these cells undergo a signifi-
cant phenotypic change with age.
To determine whether the lack of DR3 expression on
CD14+ monocytes affected osteoclast formation, we per-
formed osteoclastogenesis assays. No difference in osteo-
clast potential was observed between the post-menopausal
and osteoporotic cultures. However, levels of osteoclast
formation were lower than we have previously reported
for pre-menopausal controls under the same conditions
[14]. This is in contrast to work published by D’Amelio et
al. [7] who demonstrated significantly higher levels of
‘spontaneous’ osteoclast formation from osteoporotic pa-
tient PBMC cultures compared to pre-menopausal con-
trols. The apparent discrepancy between the two studies
however, could be explained by differences in methods
used. In the D’Amelio et al. [7] study whole PBMC cul-
tures were utilized as compared to CD14+ monocyte cul-
tures used in this study. Increased production of pro-
osteoclastogenic cytokines RANKL, MCSF and TNFα by
PBMCs post-menopause has been demonstrated by a
number of groups [7–9]. Elevated levels of these cytokines
would have a significant effect on osteoclast formation in
these cultures. Of the PBMCs, T cells are believed to play
a particularly critical role in bone loss associated with
oestrogen-deficiency [4]; loss of oestrogen has been ob-
served to increase T cell expression of TNFα, RANKL and
IL-17 [8, 29, 30]. Importantly, signalling by TL1A through
DR3 on CD4+ T cells has been shown to induce expres-
sion of TNFα and IL-17 [17, 31, 32]; suggesting that
changes in DR3 and TL1A signalling on these cells could
indirectly affect osteoclast formation by modulating T cell
cytokine expression. To investigate this we performed a
murine model of ovariectomy and investigated splenic
CD4+ T cell DR3 expression 1 and 8 weeks post-surgery as
indicators of early and late post-menopause. Interestingly,
DR3 expression on CD4+ T cells was significantly elevated
at 1 week but not 8 weeks post-surgery. This raises the
very significant possibility that elevated CD4+ T cell DR3
expression may contribute to the increased bone loss ob-
served in early menopause.
a
b
Fig. 4 Expression of DR3 on Splenic CD4+ T Cells following
Ovairectomy. Female BALB/c mice (12 weeks) underwent either
sham or ovariectomy (OVX) surgery. The (a) number of DR3+ splenic
CD4+ T cells and (b) DR3 expression (MFI) was analysed by flow
cytometry 1 week and 8 weeks post-surgery. One week post-surgery
significantly increased CD4+ DR3+ cell numbers (p < 0.05) and DR3
expression (p < 0.01) was observed in the OVX cohort compared to
the sham cohort (p < 0.05). At 8 weeks post-surgery no difference
was detected between the sham and OVX cohorts. Statistical
analysis performed by unpaired student’s t-test
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In conclusion, we have demonstrated for the first time
that loss of oestrogen has a significant effect on DR3 and
TL1A expression. We reveal that post-menopause the
ability to induce DR3 expression is lost from circulating
CD14+ monocytes and serum TL1A levels trend down-
wards compared to pre-menopausal females. In contrast
however, serum TL1A levels in post-menopausal osteo-
porotic females are comparable to pre-menopausal. How-
ever, due to the low numbers of patients recruited to the
study, further work is required before the exact effect of
menopause on DR3 and TL1A expression can be revealed.
In addition, we further identify in a murine ovariectomy
model of oestrogen loss that CD4+ T cell DR3 expression
is significantly upregulated early on, suggesting that DR3 /
TL1A signalling could indirectly contribute to the in-
creased bone loss observed post-menopause through
modulation of T cell activity.
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